Table 3. Multivariate Cox regression analysis of V-ATPase V1E1 and other covariates for ESCC patients' survival rate.
| Predictors | Disease-free survival | Overall survival | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR1 (95% CI2) | P value | |
| Age | ||||
| 0–65 | 1.00 | 1.00 | ||
| 65+ | 1.103 (0.6–1.9) | 0.720 | 1.025 (0.6–1.9) | 0.935 |
| TNM Stage | ||||
| I | 1.00 | 1.00 | ||
| II | 2.320 (0.9–6.1) | 0.093 | 3.222 (0.9–11.0) | 0.062 |
| III | 4.325 (1.7–11.1) | < 0.003** | 7.017 (2.1–22.9) | 0.002** |
| IV | 7.498 (2.7–20.7) | < 0.001** | 9.556 (2.7–34.0) | 0.001** |
| Chemotherapy | ||||
| Absent | 1.00 | 1.00 | ||
| Positive | 1.062 (0.8–1.4) | 0.632 | 1.116 (0.6–1.5) | 0.410 |
| Radiation therapy | ||||
| Absent | 1.00 | 1.00 | ||
| Positive | 0.722 (0.6–0.9) | 0.004** | 0.732 (0.6–0.9) | 0.010* |
| V-ATPase V1E1 | ||||
| Negative | 1.00 | 1.00 | ||
| Positive | 1.748 (1.1–2.8) | 0.018* | 1.394 (0.9–2.3) | 0.188 |
1
HR, Hazard Ratio. *P < 0.05, **P < 0.01.
2
CI, Confidence interval. *P < 0.05, **P < 0.01.